Prolactin, Inflammation, and Parkinson's Severity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Idiopathic Parkinson Disease, Prolactin, Prolactin Levels, Inflammation. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Turkey (Türkiye)
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Relationship of Prolactin and Inflammatory Markers With Parkinson's Disease Severity: Clinical and Biochemical Evaluation
Overview
This cross-sectional observational study aims to evaluate the relationship between serum prolactin levels, peripheral inflammatory markers (NLR, PLR, SII, CRP), and disease severity in patients with Parkinson's disease (PD). A total of at least 300 patients diagnosed with idiopathic PD will be included. Disease severity will be assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) and the Modified Hoehn-Yahr staging system. Serum and salivary prolactin levels will be measured using ELISA, while inflammatory markers will be calculated from routine blood tests. The study seeks to clarify whether prolactin and systemic inflammation indicators may serve as non-invasive biomarkers for disease progression and prognosis in PD, with particular emphasis on postmenopausal women.
Primary outcome measures
- Systemic inflammatory markers [Time frame: 1 year later]
- Prolactin Level [Time frame: 1 year later]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years
- Diagnosis of idiopathic Parkinson's disease confirmed by a neurologist
- Both male and postmenopausal female patients
- Patients able to provide informed consent
- Clinically stable enough to undergo blood and saliva sampling, as well as neurological assessment
Exclusion criteria
- Premenopausal female patients
- Patients with secondary or atypical parkinsonism (e.g., drug-induced, vascular, atypical parkinsonian syndromes)
- Known endocrine disorders affecting prolactin levels (e.g., prolactinoma, pituitary adenoma, hypothyroidism)
- Use of medications known to alter prolactin secretion (e.g., antipsychotics, dopamine antagonists, estrogen therapy)
- History of other neurodegenerative diseases (e.g., Alzheimer's, Huntington's)
- Presence of active infection, chronic inflammatory disease, or malignancy
- Severe renal, hepatic, or cardiac failure
- Inability to provide informed consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
Turkey (Türkiye) · 1 center
- Çanakkale Onsekiz Mart University — Çanakkale
Identifiers
NCT: NCT07163156 · COMU-FNN-1 · NOT YET